Posted inCardiagtech

Heartburn Differential Diagnosis: A Comprehensive Guide to Gastroesophageal Reflux Disease and Mimicking Conditions

No Comments

Introduction

Gastroesophageal reflux disease (GERD) is a prevalent chronic condition characterized by the backward flow of stomach contents into the esophagus. This reflux can manifest as non-erosive reflux disease (NERD) or erosive esophagitis (EE). GERD significantly impacts patient quality of life and imposes a substantial economic burden due to both direct and indirect healthcare costs. It is estimated that around 20% of adults in the United States suffer from GERD. The underlying cause of GERD is multifaceted, stemming from intrinsic and structural factors that disrupt the esophagogastric junction barrier, leading to esophageal exposure to stomach acid. While heartburn and regurgitation are hallmark symptoms, GERD can also present atypically with extra-esophageal symptoms including chest pain, dental erosion, chronic cough, laryngitis, or asthma. Based on endoscopic and microscopic findings, GERD is categorized into NERD, EE, and Barrett’s esophagus (BE). NERD is the most common form, affecting 60-70% of GERD patients, followed by EE and BE in 30% and 6-12% respectively. Lifestyle adjustments and proton pump inhibitors (PPIs) have been the traditional mainstays of GERD management. However, medically refractory GERD is becoming increasingly common, necessitating a more personalized treatment approach. It’s crucial to remember that while heartburn is a cardinal symptom of GERD, it’s also a common complaint in various other conditions. Therefore, understanding the Heartburn Differential Diagnosis is essential for accurate diagnosis and effective management. This article will delve into the complexities of GERD, with a particular focus on differentiating heartburn caused by GERD from other conditions that can mimic its symptoms.

Etiology of GERD

The precise etiology of GERD remains elusive. However, numerous risk factors have been identified as contributors to its development. Motor dysfunctions, such as impaired esophageal motility leading to reduced acid clearance, compromised lower esophageal sphincter (LES) tone, transient LES relaxations (TLESRs), and delayed gastric emptying, are all implicated in GERD. Anatomical factors like hiatal hernia and increased intra-abdominal pressure, often seen in obesity, are also associated with a higher GERD risk. A meta-analysis by Hampel H et al. demonstrated a link between obesity and increased risk of GERD symptoms, erosive esophagitis, and esophageal cancer. The ProGERD study further confirmed that the likelihood of erosive disease rises with increasing body mass index (BMI). Additional risk factors independently linked to GERD symptoms include age 50 and over, low socioeconomic status, smoking, excessive alcohol consumption, connective tissue disorders, pregnancy, postprandial supine position, and certain medications such as anticholinergics, benzodiazepines, NSAIDs or aspirin, nitroglycerin, albuterol, calcium channel blockers, antidepressants, and glucagon.

Epidemiology of GERD

GERD is a widespread gastrointestinal disorder, affecting approximately 20% of adults in Western populations. Systematic reviews suggest the prevalence in the US ranges from 18.1% to 27.8%. The actual prevalence may be even higher due to the accessibility of over-the-counter acid-reducing medications. While some studies suggest a slightly higher prevalence in men, a large meta-analysis by Eusebi et al. indicated a marginally higher pooled prevalence of GERD symptoms in women (16.7%) compared to men (15.4%). Interestingly, women with GERD symptoms are more likely to have NERD, while men are more prone to erosive esophagitis. However, men with long-standing GERD have a higher incidence of Barrett’s esophagus (23%) compared to women (14%).

Pathophysiology of GERD

The pathophysiology of GERD is complex and involves several interacting mechanisms, including LES function, hiatal hernia, esophageal mucosal defense, and esophageal motility.

Impaired Lower Esophageal Sphincter (LES) Function and Transient Lower Esophageal Sphincter Relaxations (TLESRs)

The LES, a 3-4 cm segment of smooth muscle at the esophagogastric junction (EGJ), along with the crural diaphragm, forms a critical barrier preventing gastric content reflux. Normally, the LES maintains a high-pressure zone above intragastric pressure, relaxing transiently after meals to allow food passage. In GERD patients, frequent TLESRs, not triggered by swallowing, can occur, causing intragastric pressure to exceed LES pressure and allowing reflux. TLESRs are responsible for a significant portion (48-73%) of GERD symptoms. Factors like alcohol, smoking, caffeine, pregnancy, nitrates, and calcium channel blockers can influence LES tone and TLESRs.

Hiatal Hernia

Hiatal hernia, a common condition, often coexists with GERD and can exacerbate it. While hiatal hernias can exist without symptoms, they can impair LES function. Studies show patients with GERD and large hiatal hernias exhibit shorter, weaker LES, leading to increased reflux and more severe esophagitis. One study found hiatal hernias in 94% of patients with reflux esophagitis.

Impaired Esophageal Mucosal Defense

The esophageal mucosa has protective mechanisms against refluxed substances. Prolonged exposure to acidic gastric contents (hydrochloric acid and pepsin) and alkaline duodenal contents (bile salts and pancreatic enzymes) can overwhelm this defense barrier, causing mucosal damage. Delayed gastric emptying may also contribute to GERD by increasing gastric distention and reflux exposure.

Defective Esophageal Peristalsis

Esophageal peristalsis normally clears refluxed gastric contents and salivary bicarbonate neutralizes acid. Impaired peristalsis, seen in about 21% of GERD patients, can reduce reflux clearance, leading to more severe symptoms and mucosal damage.

Histopathology of GERD

The esophageal squamous epithelium acts as a barrier against reflux. In GERD and NERD, this epithelial defense is often compromised. Histopathological findings in GERD, while not entirely specific, include inflammation, basal cell hyperplasia, papilla elongation, and dilated intercellular spaces. These microscopic features, in combination, aid in the diagnosis.

History and Physical Examination in GERD

Typical GERD symptoms are heartburn and regurgitation. Heartburn is described as a retrosternal burning sensation, often radiating to the neck, typically occurring after meals or when lying down. Regurgitation involves the reflux of acidic stomach contents into the mouth or hypopharynx. Atypical GERD presents with extraesophageal symptoms like chest pain, chronic cough, asthma, laryngitis, dental erosions, dysphonia, hoarseness, and globus sensation. A thorough history and physical exam are crucial, not only to identify GERD symptoms but also to consider the heartburn differential diagnosis and rule out other conditions.

Evaluation of GERD and Heartburn Differential Diagnosis

Diagnosing GERD can be challenging as there is no single gold standard test. Diagnosis relies on symptom presentation, response to PPI therapy, esophagogastroduodenoscopy (EGD), and ambulatory reflux monitoring. Crucially, when evaluating heartburn, clinicians must consider a broad differential diagnosis to ensure accurate diagnosis and management.

Proton Pump Inhibitor (PPI) Trial

In patients with typical heartburn and regurgitation without alarm symptoms (dysphagia, odynophagia, anemia, weight loss, hematemesis), an empiric PPI trial can be diagnostic. Symptom improvement with PPIs suggests GERD. However, some studies question the accuracy of this approach. A failed PPI trial necessitates further investigation into the heartburn differential diagnosis.

Esophagogastroduodenoscopy (EGD)

EGD is recommended for patients with GERD symptoms and alarm symptoms to rule out complications like erosive esophagitis, Barrett’s esophagus, strictures, adenocarcinoma, or peptic ulcer disease. EGD is also important in the heartburn differential diagnosis, as it can identify other esophageal conditions. For patients with chest pain and suspected cardiac issues, cardiac evaluation should be prioritized. In cases of noncardiac chest pain potentially due to GERD, EGD and pH monitoring are recommended before PPI initiation. Current guidelines do not recommend routine Helicobacter pylori testing in GERD patients.

Radiographic Studies

Barium swallow studies can detect moderate to severe esophagitis, strictures, hiatal hernia, and tumors. However, they are not primary diagnostic tools for GERD and have limited value in the heartburn differential diagnosis compared to endoscopy.

Ambulatory Esophageal Reflux Monitoring

Ambulatory reflux monitoring (pH or pH-impedance) is crucial for medically refractory GERD and in patients with extraesophageal symptoms suggestive of GERD, especially when considering the heartburn differential diagnosis. It assesses symptom correlation with abnormal acid exposure and is the only test to quantify pathological acid exposure and reflux frequency. Preoperative ambulatory pH monitoring is recommended for patients without erosive esophagitis undergoing anti-reflux surgery.

Heartburn Differential Diagnosis: Conditions Mimicking GERD

It is critical to consider other conditions in the heartburn differential diagnosis. Heartburn is not exclusive to GERD and can be a symptom of various other disorders. Accurate differentiation is essential for appropriate treatment. Key conditions to consider include:

  • Cardiac Conditions:

    • Coronary Artery Disease (CAD) / Angina: Cardiac chest pain can often be mistaken for heartburn. Angina is typically exertional, described as chest tightness, pressure, or squeezing, and may radiate to the arm, jaw, or back. It’s crucial to rule out cardiac causes, especially in patients with risk factors for CAD. ECG, cardiac enzymes, and stress tests may be necessary.
    • Pericarditis: Inflammation of the pericardium can cause chest pain that may mimic heartburn. Pericarditis pain is often sharp, pleuritic, and may be relieved by sitting up and leaning forward.

  • Esophageal Disorders (Non-GERD):

    • Achalasia: This esophageal motility disorder impairs LES relaxation and peristalsis, leading to dysphagia, regurgitation, and chest pain that can be mistaken for heartburn. Manometry is the diagnostic test.
    • Esophageal Spasm: Diffuse esophageal spasm can cause intense chest pain, often described as squeezing or gripping, which can be similar to heartburn or angina. Manometry and esophageal provocation tests can aid diagnosis.
    • Eosinophilic Esophagitis (EoE): EoE is characterized by esophageal eosinophilic infiltration, causing dysphagia, chest pain, and heartburn-like symptoms, particularly in younger individuals. Endoscopy with biopsy is essential for diagnosis.
    • Pill-induced Esophagitis: Certain medications (e.g., NSAIDs, bisphosphonates, antibiotics) can cause esophageal irritation and heartburn. Medication history is crucial.
    • Infectious Esophagitis: Infections (e.g., Candida, Herpes, CMV) can cause esophagitis with pain and heartburn, especially in immunocompromised individuals. Endoscopy with biopsy is diagnostic.

  • Gastric and Duodenal Disorders:

    • Peptic Ulcer Disease (PUD): Gastric or duodenal ulcers can cause epigastric pain that may radiate to the chest and be mistaken for heartburn. PUD pain is often related to meals (worse with fasting in duodenal ulcers, worse after meals in gastric ulcers). Endoscopy is diagnostic.
    • Gastritis and Functional Dyspepsia: Non-ulcer dyspepsia can cause upper abdominal discomfort and heartburn-like symptoms without evidence of ulcers or esophagitis. Diagnosis of exclusion, after ruling out other organic causes.
    • Gastroparesis: Delayed gastric emptying can lead to upper abdominal fullness, nausea, and heartburn-like symptoms. Gastric emptying studies are diagnostic.

  • Biliary and Pancreatic Disorders:

    • Biliary Colic / Gallstones: Pain from gallstones can radiate to the chest and upper abdomen, mimicking heartburn. RUQ ultrasound is diagnostic.
    • Pancreatitis: Upper abdominal pain from pancreatitis can radiate to the chest and back, and may be mistaken for severe heartburn. Amylase and lipase levels, and imaging (CT scan) are diagnostic.

  • Musculoskeletal Chest Pain:

    • Costochondritis: Inflammation of the rib cartilage can cause chest wall pain that can be confused with heartburn. Pain is typically localized, reproducible with palpation, and worsened by movement.

  • Psychiatric Conditions:

    • Anxiety and Panic Disorder: Anxiety and panic attacks can manifest with somatic symptoms, including chest discomfort and sensations that may be interpreted as heartburn. Psychological evaluation is needed.

This extensive heartburn differential diagnosis highlights the need for a comprehensive evaluation beyond just assuming GERD. Patient history, physical examination, and appropriate investigations are essential for accurate diagnosis.

Treatment and Management of GERD

The goals of GERD management are symptom relief and prevention of complications like esophagitis, BE, and esophageal adenocarcinoma. Treatment strategies include lifestyle modifications, medical therapy, surgical options, and endoluminal therapies.

Lifestyle Modifications

Lifestyle changes are fundamental to GERD management. Weight loss is crucial for overweight or obese individuals, as obesity is a significant risk factor. Patients should avoid meals 3 hours before bedtime and practice good sleep hygiene. Elevating the head of the bed can also reduce nighttime reflux. Dietary modifications, such as avoiding chocolate, caffeine, spicy foods, citrus, and carbonated beverages, are often suggested, although current guidelines do not routinely recommend them.

Medical Therapy

Medical therapy is indicated when lifestyle modifications are insufficient. Options include antacids, histamine-2 receptor antagonists (H2RAs), PPIs, and prokinetic agents. PPIs are generally considered the most effective medical treatment for both erosive and non-erosive GERD, demonstrating better symptom control, esophagitis healing, and reduced relapse rates compared to H2RAs. ACG guidelines recommend once-daily PPI dosing before the first meal. Twice-daily dosing or adjusted timing may be needed for incomplete responders, especially with nighttime symptoms. Bedtime H2RAs can be added for nocturnal symptoms not controlled by PPIs. Prokinetic agents have limited use in GERD due to limited efficacy and potential side effects.

Surgical Therapy

Surgical management is considered for medically refractory GERD, medication intolerance, large hiatal hernias, or patient preference to avoid long-term medication. Surgical options include laparoscopic Nissen fundoplication, laparoscopic anterior 180° fundoplication, and bariatric surgery for obese patients. Nissen fundoplication has been the gold standard. Gastric bypass is increasingly common for obese GERD patients. Preoperative ambulatory pH monitoring and esophageal manometry are recommended. While some studies suggest surgical benefits over medical therapy, others show uncertain benefits and risks of postoperative complications like bloating, dysphagia, and belching. Roux-en-Y gastric bypass (RYGB) is the most effective bariatric surgery for GERD in obese patients.

Endoluminal Therapy

Minimally invasive endoscopic therapies for GERD include magnetic sphincter augmentation (MSA) and transoral incisionless fundoplication (TIF). Meta-analyses suggest TIF 2.0 can improve esophageal pH, reduce PPI use, and improve quality of life. MSA also shows promise, with short-term outcomes comparable to Nissen fundoplication.

Differential Diagnosis (Revisited and Expanded)

  • Coronary Artery Disease: Differentiate based on exertional nature of angina, ECG, cardiac enzymes, stress testing.
  • Achalasia: Manometry is diagnostic, symptoms include dysphagia and regurgitation more prominently than typical GERD.
  • Eosinophilic Esophagitis (EoE): Endoscopy with biopsy shows eosinophilic infiltration. Consider in younger patients with dysphagia and heartburn.
  • Non-ulcer Dyspepsia (Functional Dyspepsia): Diagnosis of exclusion after ruling out organic causes. Symptoms may overlap with GERD but without esophagitis.
  • Rumination Syndrome: Characterized by effortless regurgitation of recently ingested food, often shortly after meals. Behavioral therapy is the primary treatment.
  • Esophageal Diverticula: Usually asymptomatic but large diverticula can cause regurgitation and dysphagia. Barium swallow or endoscopy can diagnose.
  • Gastroparesis: Gastric emptying study confirms delayed emptying. Symptoms include nausea, vomiting, early satiety in addition to heartburn.
  • Esophageal and Gastric Neoplasm: Endoscopy with biopsy is essential to rule out malignancy in patients with alarm symptoms.
  • Peptic Ulcer Disease (PUD): Endoscopy is diagnostic. PUD pain is often related to meals and may be relieved by antacids, similar to GERD, but location and pattern can differ.
  • Biliary Colic/Gallstones: RUQ ultrasound, pain pattern different from typical heartburn, often related to fatty meals.
  • Pancreatitis: Amylase, lipase, CT scan. Severe abdominal pain radiating to back, different from typical heartburn.
  • Costochondritis: Physical exam, localized chest wall pain, reproducible on palpation, musculoskeletal nature.
  • Anxiety/Panic Disorder: Psychological evaluation, symptoms often occur in panic attacks, associated with other anxiety symptoms.

Complications of GERD

  • Erosive Esophagitis (EE): Esophageal mucosal erosions or ulcers, graded by the Los Angeles classification. Can be asymptomatic or worsen GERD symptoms.
  • Esophageal Strictures: Chronic acid exposure can lead to esophageal scarring and stricture formation, causing dysphagia. Dilation and PPI therapy are recommended.
  • Barrett Esophagus (BE): Metaplastic columnar epithelium replaces squamous epithelium in the distal esophagus due to chronic acid exposure. Increases risk of esophageal adenocarcinoma. Surveillance endoscopy is recommended.

Enhancing Healthcare Team Outcomes in GERD Management

Effective GERD management requires an interprofessional team approach involving primary care providers, gastroenterologists, otolaryngologists, pulmonologists, bariatric surgeons, and pharmacists. Primary care physicians play a crucial role in initial assessment, identifying alarm symptoms, and ruling out cardiac causes. They should counsel patients on lifestyle modifications. Gastroenterologists manage complex cases, perform endoscopy, and guide medical and surgical management. Otolaryngologists and pulmonologists consider GERD in patients with atypical symptoms like cough, laryngitis, and asthma. Bariatric surgeons manage obese GERD patients. Pharmacists ensure appropriate medication use and address drug-related issues. A multidisciplinary approach improves patient outcomes and quality of life in GERD management, particularly when considering the broad heartburn differential diagnosis.

Review Questions

(Review questions from the original article would be included here if needed, but are not specifically requested for this rewritten version)

References

(References from the original article are listed below, maintaining the original numbering)

  1. Fass R, Frazier R. The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease. Therap Adv Gastroenterol. 2017 Feb;10(2):243-251. [PMC free article: PMC5298478] [PubMed: 28203282]
  2. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014 Jun;63(6):871-80. [PMC free article: PMC4046948] [PubMed: 23853213]
  3. Hom C, Vaezi MF. Extraesophageal manifestations of gastroesophageal reflux disease. Gastroenterol Clin North Am. 2013 Mar;42(1):71-91. [PubMed: 23452632]
  4. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R., Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943. [PubMed: 16928254]
  5. Fass R, Ofman JJ. Gastroesophageal reflux disease–should we adopt a new conceptual framework? Am J Gastroenterol. 2002 Aug;97(8):1901-9. [PubMed: 12190152]
  6. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol. 2007 Feb;41(2):131-7. [PubMed: 17245209]
  7. Argyrou A, Legaki E, Koutserimpas C, Gazouli M, Papaconstantinou I, Gkiokas G, Karamanolis G. Risk factors for gastroesophageal reflux disease and analysis of genetic contributors. World J Clin Cases. 2018 Aug 16;6(8):176-182. [PMC free article: PMC6107529] [PubMed: 30148145]
  8. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005 Aug 02;143(3):199-211. [PubMed: 16061918]
  9. Malfertheiner P, Nocon M, Vieth M, Stolte M, Jaspersen D, Koelz HR, Labenz J, Leodolter A, Lind T, Richter K, Willich SN. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care–the ProGERD study. Aliment Pharmacol Ther. 2012 Jan;35(1):154-64. [PubMed: 22070159]
  10. El-Serag HB, Hashmi A, Garcia J, Richardson P, Alsarraj A, Fitzgerald S, Vela M, Shaib Y, Abraham NS, Velez M, Cole R, Rodriguez MB, Anand B, Graham DY, Kramer JR. Visceral abdominal obesity measured by CT scan is associated with an increased risk of Barrett’s oesophagus: a case-control study. Gut. 2014 Feb;63(2):220-9. [PMC free article: PMC3976427] [PubMed: 23408348]
  11. Mohammed I, Nightingale P, Trudgill NJ. Risk factors for gastro-oesophageal reflux disease symptoms: a community study. Aliment Pharmacol Ther. 2005 Apr 01;21(7):821-7. [PubMed: 15801917]
  12. Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018 Mar;67(3):430-440. [PubMed: 28232473]
  13. Patti MG. An Evidence-Based Approach to the Treatment of Gastroesophageal Reflux Disease. JAMA Surg. 2016 Jan;151(1):73-8. [PubMed: 26629969]
  14. Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J. Prevalence of gastro-oesophageal reflux symptoms and the influence of age and sex. Scand J Gastroenterol. 2004 Nov;39(11):1040-5. [PubMed: 15545159]
  15. Kim SY, Jung HK, Lim J, Kim TO, Choe AR, Tae CH, Shim KN, Moon CM, Kim SE, Jung SA. Gender Specific Differences in Prevalence and Risk Factors for Gastro-Esophageal Reflux Disease. J Korean Med Sci. 2019 Jun 02;34(21):e158. [PMC free article: PMC6543060] [PubMed: 31144481]
  16. Lin M, Gerson LB, Lascar R, Davila M, Triadafilopoulos G. Features of gastroesophageal reflux disease in women. Am J Gastroenterol. 2004 Aug;99(8):1442-7. [PubMed: 15307857]
  17. Savarino E, Bredenoord AJ, Fox M, Pandolfino JE, Roman S, Gyawali CP., International Working Group for Disorders of Gastrointestinal Motility and Function. Expert consensus document: Advances in the physiological assessment and diagnosis of GERD. Nat Rev Gastroenterol Hepatol. 2017 Nov;14(11):665-676. [PubMed: 28951582]
  18. De Giorgi F, Palmiero M, Esposito I, Mosca F, Cuomo R. Pathophysiology of gastro-oesophageal reflux disease. Acta Otorhinolaryngol Ital. 2006 Oct;26(5):241-6. [PMC free article: PMC2639970] [PubMed: 17345925]
  19. Mittal RK, McCallum RW. Characteristics and frequency of transient relaxations of the lower esophageal sphincter in patients with reflux esophagitis. Gastroenterology. 1988 Sep;95(3):593-9. [PubMed: 3396810]
  20. Kahrilas PJ, Lin S, Chen J, Manka M. The effect of hiatus hernia on gastro-oesophageal junction pressure. Gut. 1999 Apr;44(4):476-82. [PMC free article: PMC1727465] [PubMed: 10075953]
  21. Patti MG, Goldberg HI, Arcerito M, Bortolasi L, Tong J, Way LW. Hiatal hernia size affects lower esophageal sphincter function, esophageal acid exposure, and the degree of mucosal injury. Am J Surg. 1996 Jan;171(1):182-6. [PubMed: 8554137]
  22. Ott DJ, Gelfand DW, Chen YM, Wu WC, Munitz HA. Predictive relationship of hiatal hernia to reflux esophagitis. Gastrointest Radiol. 1985;10(4):317-20. [PubMed: 4054494]
  23. Richter J. Do we know the cause of reflux disease? Eur J Gastroenterol Hepatol. 1999 Jun;11 Suppl 1:S3-9. [PubMed: 10443906]
  24. Diener U, Patti MG, Molena D, Fisichella PM, Way LW. Esophageal dysmotility and gastroesophageal reflux disease. J Gastrointest Surg. 2001 May-Jun;5(3):260-5. [PubMed: 11360049]
  25. Kandulski A, Weigt J, Caro C, Jechorek D, Wex T, Malfertheiner P. Esophageal intraluminal baseline impedance differentiates gastroesophageal reflux disease from functional heartburn. Clin Gastroenterol Hepatol. 2015 Jun;13(6):1075-81. [PubMed: 25496815]
  26. Allende DS, Yerian LM. Diagnosing gastroesophageal reflux disease: the pathologist’s perspective. Adv Anat Pathol. 2009 May;16(3):161-5. [PubMed: 19395879]
  27. Sandhu DS, Fass R. Current Trends in the Management of Gastroesophageal Reflux Disease. Gut Liver. 2018 Jan 15;12(1):7-16. [PMC free article: PMC5753679] [PubMed: 28427116]
  28. Kellerman R, Kintanar T. Gastroesophageal Reflux Disease. Prim Care. 2017 Dec;44(4):561-573. [PubMed: 29132520]
  29. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013 Mar;108(3):308-28; quiz 329. [PubMed: 23419381]
  30. Numans ME, Lau J, de Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med. 2004 Apr 06;140(7):518-27. [PubMed: 15068979]
  31. Hirano I, Richter JE., Practice Parameters Committee of the American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol. 2007 Mar;102(3):668-85. [PubMed: 17335450]
  32. Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006 Jun 01;354(22):2340-8. [PMC free article: PMC2782772] [PubMed: 16738270]
  33. Fujiwara Y, Arakawa T, Fass R. Gastroesophageal reflux disease and sleep disturbances. J Gastroenterol. 2012 Jul;47(7):760-9. [PubMed: 22592763]
  34. Zhang JX, Ji MY, Song J, Lei HB, Qiu S, Wang J, Ai MH, Wang J, Lv XG, Yang ZR, Dong WG. Proton pump inhibitor for non-erosive reflux disease: a meta-analysis. World J Gastroenterol. 2013 Dec 07;19(45):8408-19. [PMC free article: PMC3857466] [PubMed: 24363534]
  35. Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD003244. [PubMed: 17443524]
  36. Chang P, Friedenberg F. Obesity and GERD. Gastroenterol Clin North Am. 2014 Mar;43(1):161-73. [PMC free article: PMC3920303] [PubMed: 24503366]
  37. Garg SK, Gurusamy KS. Laparoscopic fundoplication surgery versus medical management for gastro-oesophageal reflux disease (GORD) in adults. Cochrane Database Syst Rev. 2015 Nov 05;2015(11):CD003243. [PMC free article: PMC8278567] [PubMed: 26544951]
  38. Gerson L, Stouch B, Lobonţiu A. Transoral Incisionless Fundoplication (TIF 2.0): A Meta-Analysis of Three Randomized, Controlled Clinical Trials. Chirurgia (Bucur). 2018 Mar-Apr;113(2):173-184. [PubMed: 29733015]
  39. Skubleny D, Switzer NJ, Dang J, Gill RS, Shi X, de Gara C, Birch DW, Wong C, Hutter MM, Karmali S. LINX® magnetic esophageal sphincter augmentation versus Nissen fundoplication for gastroesophageal reflux disease: a systematic review and meta-analysis. Surg Endosc. 2017 Aug;31(8):3078-3084. [PubMed: 27981382]
  40. Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999 Aug;45(2):172-80. [PMC free article: PMC1727604] [PubMed: 10403727]
  41. Wang KK, Sampliner RE., Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroenterol. 2008 Mar;103(3):788-97. [PubMed: 18341497]

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *